bi 1569912
Small moleculeexperimental
Clinical trial activity
8 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 21, 2020 (NCT04445090)
Timeline
Indications
Mechanism of action
- Glutamate [NMDA] receptor subunit epsilon 2ALLOSTERIC ANTAGONIST
GRIN2B allosteric antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06558344 | Phase 2 | Sep 16, 2024 | Boehringer Ingelheim |
| NCT06520553 | Phase 1 | Aug 20, 2024 | Boehringer Ingelheim |
| NCT06367153 | Phase 1 | May 7, 2024 | Boehringer Ingelheim |
| NCT06280235 | Phase 2 | Mar 7, 2024 | Boehringer Ingelheim |
| NCT04978506 | Phase 1 | Aug 11, 2021 | Boehringer Ingelheim |
| NCT04958252 | Phase 1 | Aug 5, 2021 | Boehringer Ingelheim |
| NCT04937829 | Phase 1 | Jul 20, 2021 | Boehringer Ingelheim |
| NCT04445090 | Phase 1 | Jul 21, 2020 | Boehringer Ingelheim |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 8 | 8 | 2 | 2020 |
1 organizations
Page 1 / 1